Qube Research & Technologies (QRT)’s Beam Therapeutics BEAM Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.66M	Sell	194,083 -890,685	-82%	-$26.9M	0.01%	1489
2026 Q1	$25.9M	Buy	1,084,768 +685,109	+171%	+$19M	0.03%	731
2025 Q4	$11.1M	Buy	399,659 +329,228	+467%	+$8.4M	0.01%	1280
2025 Q3	$1.71M	Sell	70,431 -523,384	-88%	-$10.4M	﹤0.01%	2303
2025 Q2	$10.1M	Buy	+593,815	New	+$10.3M	0.01%	1279
2024 Q3	–	Sell	-102,359	Closed	-$2.4M	–	3323
2024 Q2	$2.4M	Buy	102,359 +4,304	+4%	+$106K	﹤0.01%	1549
2024 Q1	$3.24M	Buy	+98,055	New	+$3.05M	0.01%	1476
2023 Q2	–	Sell	-114,568	Closed	-$3.51M	–	2402
2023 Q1	$3.51M	Buy	+114,568	New	+$4.52M	0.02%	774
2022 Q2	–	Sell	-18,773	Closed	-$1.08M	–	2502
2022 Q1	$1.08M	Buy	+18,773	New	+$1.23M	0.01%	1136
2021 Q4	–	Sell	-4,315	Closed	-$375K	–	2527
2021 Q3	$375K	Buy	4,315 +1,640	+61%	+$165K	﹤0.01%	1376
2021 Q2	$344K	Sell	2,675 -1,311	-33%	-$104K	﹤0.01%	1496
2021 Q1	$319K	Buy	+3,986	New	+$379K	0.01%	1424

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BEAM Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Beam Therapeutics (BEAM) stake by 82% in Q2 2026, selling an estimated $26.9M and leaving 194,083 shares worth $6.66M. The position accounts for 0.01% of the portfolio, ranked #1489.

Qube Research & Technologies (QRT) first reported a position in BEAM in Q1 2021 and has held it in 12 quarters since. The position peaked at $25.9M in Q1 2026. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Qube Research & Technologies (QRT) held 194,083 shares of Beam Therapeutics worth $6.66M as of Q2 2026.
Qube Research & Technologies (QRT) sold 890,685 Beam Therapeutics shares in Q2 2026, an estimated $26.9M.
Beam Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1489 holding.
Qube Research & Technologies (QRT) first reported a position in Beam Therapeutics in Q1 2021 and has held it in 12 quarters since.
Qube Research & Technologies (QRT)'s Beam Therapeutics position peaked at $25.9M in Q1 2026.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.